OMEROS CORP Cost of Revenue
OMEROS CORP (OMER) reported Cost of Revenue of $798.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-12
- OMEROS CORP cost of goods and services sold for the quarter ending 2026-06-30 was $798.00K.
- OMEROS CORP cost of goods and services sold for the quarter ending 2026-03-31 was $587.00K.
- OMEROS CORP cost of goods and services sold for the quarter ending 2025-06-30 was $0.00.
- OMEROS CORP cost of goods and services sold for the quarter ending 2025-03-31 was $0.00.
- OMEROS CORP cost of goods and services sold for fiscal 2020 was $902.00K, a 4.28% increase from fiscal 2019.
- OMEROS CORP cost of goods and services sold for fiscal 2019 was $865.00K, a 68.95% increase from fiscal 2018.
- OMEROS CORP cost of goods and services sold for fiscal 2018 was $512.00K, a 52.50% decline from fiscal 2017.
- OMEROS CORP cost of goods and services sold for fiscal 2017 was $1.08M, a 23.65% decline from fiscal 2016.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $798.00K 10-Q · filed 2026-08-12 | $1.39M 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $587.00K 10-Q · filed 2026-05-13 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | |||
| 2021-09-30 | $333.00K 10-Q · filed 2021-11-09 | $675.00K derived: sum of 2 quarters · filed 2021-11-09 | $938.00K 10-Q · filed 2021-11-09 | $1.02M derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | $342.00K 10-Q · filed 2021-08-09 | $606.00K 10-Q · filed 2021-08-09 | $692.00K derived: sum of 3 quarters · filed 2021-08-09 | $1.09M derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-03-31 | $263.00K 10-Q · filed 2021-05-10 | $350.00K derived: sum of 2 quarters · filed 2021-05-10 | $751.00K derived: sum of 3 quarters · filed 2021-11-09 | $898.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $488.00K derived: sum of 2 quarters · filed 2021-11-09 | $635.00K derived: sum of 3 quarters · filed 2021-11-09 | $902.00K 10-K · filed 2021-03-01 |
| 2020-09-30 | $401.00K 10-Q · filed 2021-11-09 | $548.00K derived: sum of 2 quarters · filed 2021-11-09 | $815.00K 10-Q · filed 2021-11-09 | $1.22M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $147.00K 10-Q · filed 2021-08-09 | $414.00K 10-Q · filed 2021-08-09 | $815.00K derived: sum of 3 quarters · filed 2021-08-09 | $1.09M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $267.00K 10-Q · filed 2021-05-10 | $668.00K derived: sum of 2 quarters · filed 2021-05-10 | $946.00K derived: sum of 3 quarters · filed 2021-05-10 | $1.00M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $679.00K derived: sum of 2 quarters · filed 2021-03-01 | $734.00K derived: sum of 3 quarters · filed 2021-03-01 | $865.00K 10-K · filed 2021-03-01 |
| 2019-09-30 | $278.00K 10-Q · filed 2020-11-09 | $333.00K derived: sum of 2 quarters · filed 2020-11-09 | $464.00K 10-Q · filed 2020-11-09 | $621.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $55.00K 10-Q · filed 2020-08-10 | $186.00K 10-Q · filed 2020-08-10 | $343.00K derived: sum of 3 quarters · filed 2021-03-01 | $379.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $131.00K 10-Q · filed 2020-05-11 | $288.00K derived: sum of 2 quarters · filed 2021-03-01 | $324.00K derived: sum of 3 quarters · filed 2021-03-01 | $440.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $193.00K derived: sum of 2 quarters · filed 2021-03-01 | $309.00K derived: sum of 3 quarters · filed 2021-03-01 | $512.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | $36.00K 10-Q · filed 2019-11-12 | $152.00K derived: sum of 2 quarters · filed 2019-11-12 | $355.00K 10-Q · filed 2019-11-12 | $820.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $116.00K 10-Q · filed 2019-08-08 | $319.00K 10-Q · filed 2019-08-08 | $784.00K derived: sum of 3 quarters · filed 2020-03-02 | $968.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $203.00K 10-Q · filed 2019-05-09 | $668.00K derived: sum of 2 quarters · filed 2020-03-02 | $852.00K derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $465.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $649.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.08M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $184.00K 10-Q · filed 2018-11-08 | $613.00K 10-Q · filed 2018-11-08 | ||
| 2016-12-31 | $1.41M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |